{
    "id": 29984,
    "fullName": "SCYL3 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SCYL3-NTRK1 results from the fusion of SCYL3 and NTRK1, which results in transformation of cells as demonstrated by IL3-independent cell proliferation in culture (PMID: 28903424), and therefore, is predicted to lead to a gain of protein function. SCYL3-NTRK1 has been identified in colorectal cancer (PMID: 28903424).",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 57147,
        "geneSymbol": "SCYL3",
        "terms": [
            "SCYL3",
            "PACE-1",
            "PACE1"
        ]
    },
    "variant": "SCYL3 - NTRK1",
    "createDate": "04/30/2019",
    "updateDate": "07/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 17283,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17284,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17282,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) treatment of transformed cells in culture with SCYL3-NTRK1 inhibited IL3-independent cell proliferation (PMID: 28903424).",
            "molecularProfile": {
                "id": 32088,
                "profileName": "SCYL3 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14961,
                    "pubMedId": 28903424,
                    "title": "Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28903424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32088,
            "profileName": "SCYL3 - NTRK1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}